# Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

> **NCT04944654** · PHASE4 · TERMINATED · sponsor: **Chelsea and Westminster NHS Foundation Trust** · enrollment: 1 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** BIKTARVY 50Mg-200Mg-25Mg Tablet

## Key facts

- **NCT ID:** NCT04944654
- **Lead sponsor:** Chelsea and Westminster NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-07
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Trial set up was delayed, funding support no longer available
- **Last updated:** 2024-05-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04944654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04944654, "Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04944654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*